432 related articles for article (PubMed ID: 22633080)
1. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
Duarte R; Carvalho A; Correia A
Public Health; 2012 Sep; 126(9):760-2. PubMed ID: 22633080
[No Abstract] [Full Text] [Related]
2. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
Stout JE
Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147
[TBL] [Abstract][Full Text] [Related]
3. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group.
Gordin F; Chaisson RE; Matts JP; Miller C; de Lourdes Garcia M; Hafner R; Valdespino JL; Coberly J; Schechter M; Klukowicz AJ; Barry MA; O'Brien RJ
JAMA; 2000 Mar; 283(11):1445-50. PubMed ID: 10732934
[TBL] [Abstract][Full Text] [Related]
4. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
[TBL] [Abstract][Full Text] [Related]
5. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE
Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943
[TBL] [Abstract][Full Text] [Related]
6. Tolerability of rifampin monotherapy for latent tuberculosis infection in children.
Daskalaki I; Byun J; Dogbey MC; Tolbert-Warren C; Watson BM
Pediatr Infect Dis J; 2011 Nov; 30(11):1014-5. PubMed ID: 21997666
[No Abstract] [Full Text] [Related]
7. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
[TBL] [Abstract][Full Text] [Related]
9. Impact of adverse drug reaction and predictivity of quality of life status in tuberculosis.
Guo N; Marra F; Fitzgerald JM; Elwood RK; Marra CA
Eur Respir J; 2010 Jul; 36(1):206-8. PubMed ID: 20595167
[No Abstract] [Full Text] [Related]
10. Effectiveness and safety of the schedules of short and long term treatment for tuberculous meningoencephalitis at two hospitals of Lima--Peru.
Morales S; Ramos W; Vílchez R; Pérez J; Alvarado M
Neurologia; 2011 May; 26(4):220-6. PubMed ID: 21163196
[TBL] [Abstract][Full Text] [Related]
11. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
Fluegge KR
J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis.
Zenner D; Beer N; Harris RJ; Lipman MC; Stagg HR; van der Werf MJ
Ann Intern Med; 2017 Aug; 167(4):248-255. PubMed ID: 28761946
[TBL] [Abstract][Full Text] [Related]
13. Multiple small bowel perforations in a patient on treatment of tuberculosis.
Scriven JM; Berry D
J R Coll Surg Edinb; 1996 Oct; 41(5):353. PubMed ID: 8908966
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town.
Macnab MF; Bohmer PD; Seager JR
S Afr Med J; 1994 Jun; 84(6):325-8. PubMed ID: 7740377
[TBL] [Abstract][Full Text] [Related]
15. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
McNeill L; Allen M; Estrada C; Cook P
Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy of 6-month therapy with isoniazid and rifampin compared with isoniazid, rifampin, and pyrazinamide treatment for pleural tuberculosis.
García-Rodríguez JF; Valcarce-Pardeiro N; Álvarez-Díaz H; Mariño-Callejo A
Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2121-2126. PubMed ID: 31377953
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children.
Bright-Thomas R; Nandwani S; Smith J; Morris JA; Ormerod LP
Arch Dis Child; 2010 Aug; 95(8):600-2. PubMed ID: 20530147
[TBL] [Abstract][Full Text] [Related]
18. 4-, 5- and 6-month regimens containing isoniazid, rifampicin, pyrazinamide and streptomycin for treatment of pulmonary tuberculosis under program conditions in Hong Kong.
Chan SL; Wong PC; Tam CM
Tuber Lung Dis; 1994 Aug; 75(4):245-50. PubMed ID: 7949069
[TBL] [Abstract][Full Text] [Related]
19. Treatment of latent tuberculosis infection.
Vernon A
Semin Respir Crit Care Med; 2013 Feb; 34(1):67-86. PubMed ID: 23460007
[TBL] [Abstract][Full Text] [Related]
20. Treatment of latent tuberculosis infection.
Parekh MJ; Schluger NW
Ther Adv Respir Dis; 2013 Dec; 7(6):351-6. PubMed ID: 24056289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
